Психические расстройства в общей медицине. №3 2016

Депрессия в офтальмологии – причина и следствие глазных болезней (обзор литературы)

Р.А.Беккер1, Ю.В.Быков2

1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310

Стр. 36-42

5222 просмотров

Опубликовано: 17 октября 2016

Аннотация / Abstract

Депрессивные расстройства в офтальмологической практике встречаются достаточно часто (не менее 12% средней тяжести и 13% тяжелых депрессий). С другой стороны, не менее часто наблюдаются офтальмологические последствия депрессии и ее лечения в психиатрической практике. В обзоре рассмотрены данные о статистической корреляции этих явлений, приводятся патогенетические обоснования их взаимосвязи, рассматриваются офтальмологические побочные эффекты психиатрического лечения и даются рекомендации по налаживанию взаимодействия психиатров и окулистов с целью своевременного выявления и лечения этих нарушений. Ключевые слова: депрессивные расстройства, психофармакотерапия, антидепрессанты, антипсихотики, пигментная ретинопатия, диабетическая ретинопатия, гипертензивная ретинопатия, катаракта хрусталика, конъюнктивит, блефарит. yubykov@gmail.com Для цитирования:Беккер Р.А., Быков Ю.В. Депрессия в офтальмологии – причина и следствие глазных болезней (обзор литературы). Психические расстройства в общей медицине. 2016; 3: 36–42. Major depression in ophthalmology: a cause or a consequence of an ocular disease (a systematic review of foreign literature) R.A.Bekker1, Yu.V.Bykov2 1Ben-Gurion University of the Negev. 8410501 Israel, Beer-Sheva; 2Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol', ul. Mira, d. 310 Major depressive disorder is common in ocular practice (about 12% patients seeking professional help from ophthalmologists have moderate depression, 13% severe depression). From the other hand, ocular problems are quite common among depressive patients. Such comorbidity has several pathogenetic explanations. In this article we show the statistical correlation between major depressive disorder and several ophthalmologic disorders (cataract, glaucoma, conjunctivitis etc.), discuss the pathogenesis of this comorbidity, ophthalmologic side ...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Abraham HD, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996; 16 (3): 238–41.
2. Alcántara AG. Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone? J Clin Psychopharmacol 1998; 18 (6): 487–8.
3. Ambani LM, Van Woert MH, Jr. Bowers MB. Physostigmine effects on phenothiazine-induced extrapyramidal reactions. Arch Neurol 1973; 29 (6): 444–6.
4. Aneja J, Grover S, Agarwal M, Kaushik S. Use of Electroconvulsive Therapy in the Presence of GLAUCOMA: A Case Report and Review of Literature. Indian J Psychol Med 2013; 35 (1): 80–3.
5. Arcari GT, Mendes AK, Sothern RB. A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report. Innov Clin Neurosci 2012; 9 (9): 21–4.
6. Arunagiri G., Santhi S. Migraine: an ophthalmologist's perspective. Curr Opin Ophthalmol 2003; 14 (6): 344–52.
7. Ayaki M, Kawashima M, Negishi K et al. High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors. Neuropsychiatr Dis Treat 2015; 11: 889–94.
8. Bak S, Tsiropoulos I, Kjaersgaard JO et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33: 1465–73.
9. Basile G, Epifanio A, Mandraffino R et al. Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions. J Clin Pharm Ther 2014;
39 (4): 452–4.
10. Baylor DA, Matthews G, Yau KW. Two components of electrical dark noise in toad retinal rod outer segments. J Physiol 1980; 309: 591–621.
11. Becker DE. Psychotropic drugs: implications for dental practice. Anesth Prog 2008; 55 (3): 89–99.
12. Berkowitz HL. Thiazide diuretics and lithium levels. J Clin Psychiatry 2001; 62 (1): 57.
13. Beutler JJ, Boer WH, Koomans HA. Comparative study of the effects of furosemide, ethacrynic acid and bumetanide on the lithium clearance and diluting segment reabsorption in humans. J Pharmacol Exp Ther 1992; 260 (2): 768–72.
14. Brown CS, Farmer RG, Soberman JE et al. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004; 43 (1): 33–56.
15. Bubl E, Dörr M, Philipsen A et al. Retinal contrast transfer functions in adults with and without ADHD. PLoS One 2013; 8 (5): 61728.
16. Bubl E, Ebert D, Kern E et al. Effect of antidepressive therapy on retinal contrast processing in depressive disorder. Br J Psychiatry 2012; 201: 151–8.
17. Bubl E, Kern E, Ebert D et al. Retinal dysfunction of contrast processing in major depression also apparent in cortical activity. Eur Arch Psychiatry Clin Neurosci 2015; 265 (4): 343–50.
18. Bubl E, Kern E, Ebert D. et al. Seeing gray when feeling blue? Depression can be measured in the eye of the diseased. Biol Psychiatry 2010; 68 (2): 205–98.
19. Canli T. Reconceptualizing major depressive disorder as an infectious disease. Biol Mood Anxiety Disord 2014; 4: 10.
20. Casa B, Bosio A. Levetiracetam efficacy in hallucinogen persisting perception disorders: a prospective study. J Neurol Sci 2005;
238 (1): 504.
21. Clark DB. Dental care for the patient with bipolar disorder. J Can Dent Assoc 2003; 69 (1): 20–4.
22. Colussi G, Rombolà G, Surian M et al. Effects of acute administration of acetazolamide and frusemide on lithium clearance in humans. Nephrol Dial Transplant 1989; 4 (8): 707–12.
23. Daradkeh TK, Ajlouni KM. The effect of neuroleptics on prolactinoma growth in a Jordanian schizophrenic girl. Acta Psychiatr Scand 1988; 77 (2): 228–9.
24. De Abajo FJ, Jick H, Derby L et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43–7.
25. Drago F, Panissidi G, Bellomio F et al. Effects of opiates and opioids on intraocular pressure of rabbits and humans. Clin Exp Pharmacol Physiol 1985; 12 (2): 107–13.
26. Dufrane R, Ehongo A. Treatment of glaucoma. [Article in French]. Rev Med Brux 2014; 35 (4): 291–7.
27. Estafanous MF, Kaiser PK, Baerveldt G. Retrobulbar chlorpromazine in blind and seeing painful eyes. Retina 2000; 20 (5): 555–8.
28. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29 (3): 172–91.
29. Fitzgerald PJ. Gray colored glasses: is major depression partially a sensory perceptual disorder? J Affect Disord 2013; 151 (2): 418–22.
30. Fregnan GB, Vidali M. Appearance of extrapyramidal symptoms: interaction between neuroleptics and other CNS active drugs. Pharmacology 1982; 25 (2): 102–10.
31. Garin N, Koyanagi A, Chatterji S. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. J Gerontol A Biol Sci Med Sci 2016; 71 (2): 205–14.
32. Gassler H. On the effect of thiazides in increased intraocular pressure. [Article in German]. Dtsch Gesundheitsw 1961; 16: 2309–11.
33. Gay C, Plas J, Granger B et al. Lithium poisoning. 2 unpublished interactions: acetazolamide and niflumic acid. [Article in French]. Encephale 1985; 11 (6): 261–2.
34. Good MS, Dolenc TJ, Rasmussen KG. Electroconvulsive therapy in a patient with glaucoma. J ECT 2004; 20 (1): 48–9.
35. Goulet JP, Pérusse R, Turcotte JY. Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions. Oral Surg Oral Med Oral Pathol 1992; 74 (5): 692–7.
36. Guillaume-Czitrom S, Berger C, Pajot C et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007; 46 (10): 1570–3.
37. Gupta RK. Major depression: an illness with objective physical signs. World J Biol Psychiatry 2009; 10 (3): 196–201.
38. Hamid O, Tajuddin AA. Triamterene measurements in the aqueous humor of rabbits. Pharmacol Ther 2000; 16 (6): 565–9.
39. Hariton C. Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol 1994; 258 (1–2): 85–94.
40. Hébert M, Beattie CW, Tam EM et al. Electroretinography in patients with winter seasonal affective disorder. Psychiatry Res 2004; 127 (1–2): 27–34.
41. Hermle L, Simon M, Ruchsow M et al. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol 2012; 2 (5): 199–205.
42. Hirooka K, Shiraga F. Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. Clin Ophthalmol 2007; 1 (3): 217–23.
43. Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuroprotection in the retina. Curr Pharm Des 2012; 18 (37): 6101–8.
44. Jefferis JM, Clarke MP, Taylor JP. Effect of cataract surgery on cognition, mood, and visual hallucinations in older adults. J Cataract Refract Surg 2015; 41 (6): 1241–7.
45. Jefferson JW. Diuretics are dangerous with lithium. Br Med J 1980; 281 (6249): 1217.
46. Jesus C, Jesus I, Agius M. What evidence is there to show which antipsychotics are more diabetogenic than others? Psychiatr Danub 2015; 27 (1): 42–8.
47. Kahl KG, Greggersen W, Schweiger U et al. Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2012; 262 (4): 313–20.
48. Khosla P, Kothari S, Gupta MC. Effect of haloperidol, a dopamine antagonist on aqueous humour dynamics in experimental glaucoma. Indian J Exp Biol 1996; 34 (11): 1152–4.
49. Kisilevsky E, Margolin EA. Case of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors. Can J Ophthalmol 2014; 49 (5): 114–5.
50. Krzystolik Z, Kruszyńska-Prüfferowa B. Comparison of the effects of mannitol, glycerol and furosemide on the intraocular pressure in patients with glaucoma (author's transl). [Article in Polis]. Klin Oczna 1978; 48 (7): 307–9.
51. Kung S, Ahuja Y, Iezzi R et al. Posterior vitreous detachment and retinal tear after repetitive transcranial magnetic stimulation. Brain Stimul 2011; 4 (4): 218–21.
52. Lai SW, Lin CL, Liao KF et al. Increased risk of Parkinson's disease in cataract patients: a population-based cohort study. Parkinsonism Relat Disord 2015; 21 (1): 68–71.
53. Lam RW, Remick RA. Pigmentary retinopathy associated with low-dose thioridazine treatment. Can Med Assoc J 1985; 132 (7): 737.
54. Laugharne J, Waterreus AJ, Castle DJ, Dragovic M. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry 2015; pii: 1039856215618521.
55. Li Y, Crews JE, Elam-Evans LD et al. Visual impairment and health-related quality of life among elderly adults with age-related eye diseases. Qual Life Res 2011; 20 (6): 845–52.
56. Luca M, Luca A, Calandra C. Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev 2013; 2013: 230797.
57. Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther 2012;
37 (2): 221–5.
58. McCusker S, Koola MM. Association of Ophthalmologic Disorders and Depression in the Elderly: A Review of the Literature. Prim Care Companion CNS Disord 2015; 17 (4).
59. McMonnies CW. How contact lens comfort may be influenced by psychiatric and psychological conditions and mechanisms. Clin Exp Optom 2014; 97 (4): 308–10.
60. Melkersson K, Hulting AL. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Eur Arch Psychiatry Clin Neurosci 2000; 250 (1): 6–10.
61. Mendhekar DN, Jiloha RC, Srivastava PK. Effect of risperidone on prolactinoma – a case report. Pharmacopsychiatry 2004; 37 (1): 41–2.
62. Mills KB, Gilbert DJ, Ridgway AE. The effect of topical 0.5% triamterene suspension on the intraocular pressure of open angle glaucoma patients. A single dose study. Curr Eye Res 1984; 3 (2): 273–7.
63. Modgill G, Jette N, Wang JL et al. A population-based longitudinal community study of major depression and migraine. Headache 2012; 52 (3): 422–32.
64. Morehead DB. Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol 1997;
17 (4): 327–8.
65. Nguyen TT, Wong TY, Islam FM et al. Is depression associated with microvascular disease in patients with type 2 diabetes? Depress Anxiety 2008; 25 (11): 158–62.
66. Nguyen TT, Wong TY, Islam FM et al. Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. Psychosom Med 2010; 72 (6): 535–8.
67. Niklewski G. Psychosomatic diseases of the eye – a review. [Article in German]. Z Psychosom Med Psychoanal 1982; 28 (3): 300–16.
68. Peczon JD, Grant WM. Diuretic drugs in glaucoma. Am J Ophthalmol 1968; 66 (4): 680–3.
69. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129.
70. Peragallo J, Biousse V, Newman NJ. Ocular manifestations of drug and alcohol abuse. Curr Opin Ophthalmol 2013; 24 (6): 566–73.
71. Peterzell D, Bubl E, Bach M. Factor analysis of individual differences in retinal (PERG) and cortical (VEP) visual contrast responses reveals two retinal and two cortical processes in adults with and without depression. J Vis 2015; 15 (12): 1005.
72. Pierce AM. Opiates and psychotropics: Pharmacokinetics for practitioners. Curr Psychiatry 2011; 6 (10): 83–6.
73. Pop-Jordanova N, Ristova J, Loleska S. Depression in ophthalmological patients. Prilozi 2014; 35 (2): 53–8.
74. Pradhan S, Chung SM. Retinal, ophthalmic, or ocular migraine. Curr Neurol Neurosci Rep 2004; 4 (5): 391–7.
75. Rana MA, Mady AF, Rehman BA et al. From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient. Case Rep Crit Care 2015; 2015: 714919.
76. Regen F, Le Bret N, Hildebrand M et al. Inhibition of brain retinoic acid catabolism: a mechanism for minocycline's pleiotropic actions? World J Biol Psychiatry 2015; p. 1–7.
77. Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993; 9 (3): 196–211.
78. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010; 24 (6): 501–26.
79. Rico-Sergado L, Pérez-Canales JL, Pérez-Santonja JJ et al. Severe keratomalacia after 12 months of continuous hydrogel contact lens wear in a psychiatric patient. Cont Lens Anterior Eye 2015; 38 (2): 138–41.
80. Saeki K, Obayashi K, Nishi T et al. Short-term influence of cataract surgery on circadian biological rhythm and related health outcomes (CLOCK-IOL trial): study protocol for a randomized controlled trial. Trials 2014; 15: 514.
81. Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006; 163 (11): 1891–6.
82. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999; 106: 25–36.
83. Schmidt P. Diuresis and diuretics. [Article in German]. Wien Klin Wochenschr 1971; 83 (25): 456–9.
84. Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem 2014; 75: 349–59.
85. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12–6.
86. Stepanik J. The effect of chlorothiazide (diuril, chlotride) on ocular tension in humans. [Article in German]. Ophthalmologica 1959; 138: 361–4.
87. Swanson SA, Zeng Y, Weeks M et al. The contribution of stress to the comorbidity of migraine and major depression: results from a prospective cohort study. BMJ Open 2013; 3 (3): pii: e002057.
88. Szymański A, Brozyna-Zyłka B, Sobieraj A. Various clonidine drops in treatment of glaucoma. [Article in Polish]. Klin Oczna 1992;
94 (10): 289–91.
89. Thomsen K, Leyssac PP. Acute effects of various diuretics on lithium clearance. Studies in rats on medium and low sodium diet. Ren Physiol 1986; 9 (1–2): 1–8.
90. Vipond AJ, Bakewell S, Telford R et al. Lithium toxicity. Anaesthesia 1996; 51 (12): 1156–8.
91. Watkinson S, Seewoodhary R. Cataract management: effect on patients' quality of life. Nurs Stand 2015; 29 (21): 42–8.
92. Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2000; 108 (3): 187–90.
93. Weingarten JC, Thompson TL. 2nd. The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry 1985; 7 (4): 364–6.
94. Wirz-Justice A, Graw P. Phototherapy. [Article in German]. Ther Umsch 2000; 57 (2): 71–5.
95. Witzmann R. Effect of spironolactone on intraocular pressure in glaucoma patients. [Article in German]. Klin Monbl Augenheilkd 1980; 176 (3): 445–6.
96. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vaoconstrictors. Part V of a series. J Am Dent Assoc 1999; 130 (5): 701–9.
97. Zaichik PS. Hypothiazide in the treatment of glaucoma. [Article in Russian]. Vestn Oftalmol 1962; 75: 26–32.
98. Zobor D, Strasser T, Zobor G et al. Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect? Doc Ophthalmol 2015; 130 (2): 121–30.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Депрессия в офтальмологии – причина и следствие глазных болезней (обзор литературы)

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Депрессия в офтальмологии – причина и следствие глазных болезней (обзор литературы)

Материал для специалистов

Con-Med Passport